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Abstract 
Background and Importance: Perhaps the most disabling condition seen in patients with spinal 
cord injury is spasticity. Spasticity is characterized as hyperreflexia and hypertonicity as a result 
of damage to the supraspinal tracts in the aftermath of SCI. Intrathecal baclofen (ITB) is the 
mainstay therapy for spasticity unresponsive to oral baclofen.  One of the problems associated 
with post-SCI spasticity unresponsive to ITB is development of scar tissue that prevents the 
diffusion of baclofen in the desired spinal cord area. This case offers a unique strategy to deal 
with multilevel scar tissue. 
Clinical Presentation: This is a 46-year-old paraplegic male with eighth thoracic SCI whose 
spasticity had been well managed with ITB therapy for many years but recently suffered 
intractable spasticity necessitating multiple re-operations for non-functioning ITB catheter 
secondary to extensive scar tissue and intrathecal adhesion.  A subarachnoid to subarachnoid 
shunt was placed, that solved the problem of extensive scar tissue preventing adequate baclofen 
therapy. 
Conclusion: After undergoing multilevel thoracic and lumbar laminectomies with subarachnoid-
subarachnoid spinal shunt; the patient’s spasticity was finally under control with adequate daily 
baclofen infusion. This case demonstrates a creative way to address failed ITB catheter before 
considering other measure like neuroablative procedures (i.e., rhizotomy or myelotomy). Given 
the case presented, we reinforce the recommendation that ablative procedures, which have far 
greater complications, should be reserved for patients that have failed medical or different non-
ablative therapies. 
Keywords: spinal cord injury; spasticity; intrathecal baclofen; multilevel scar tissue; 
subarachnoid-subarachnoid shunt; neuroablative 
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Background and Importance 
In 2016, the National Spinal Cord Injury statistical center estimated a prevalence of 54 cases of 
spinal cord injury (SCI) per million persons in the United States.1 Damage to the upper motor 
neurons in SCI results in poor regulation of the alpha motor neuron response to tonic muscle 
stretch reflexes that are constantly relayed to the spinal cord.2,3 Subsequently, the alpha motor 
neurons persistently fire action potentials to opposing muscle groups.  As such, damage to the 
UMN tracts causes hyper-excitable states that manifest as spasticity, hypertonia, and 
hyperreflexia. 2,3,4 Unfortunately, spasticity is an inevitable, chronic neurological sequela of 
SCI.3,5 SCI patients in chronic spastic states experience debilitating quality of life characterized 
by pressure ulcer, poor ambulation, wheelchair distress, and impaired activity of daily living.2 
There are a number of medications that have been shown to improve spasticity caused by UMN 
lesions, e.g., baclofen, benzodiazepines, dantrolene.2,6  Oral baclofen has long been known to 
reduce spasticity and hypertonicity but the dosage required will often to lead to intolerable 
adverse effects.2,7  As a result, intrathecal baclofen (ITB) has become a mainstay in the 
management of spasticity in the SCI and cerebral palsy populations.  
In this case report we present a spastic paraplegic patient with extensive scar tissue.  The 
patient’s spasticity had been well managed with ITB therapy for many years but recently 
suffered severe unremitting truncal and lower extremity spasticity necessitating multiple re-
operations for non-functioning ITB catheter secondary to extensive scar tissue and intrathecal 
adhesion.  We present a novel unpublished manner in dealing with scar tissue to improve patient 
spasticity due to SCI. 
Clinical Presentation 
The patient is a 46-year-old male with a past medical history significant for paraplegia, 
neurogenic bowel and bladder, and chronic spasticity secondary to severe traumatic brain injury 
(TBI) and eighth thoracic level (T8) SCI sustained in a motor vehicle accident (MVA).  The 
patient’s spasticity was previously well managed with ITB infusion for almost 20 years. His 
original intrathecal catheter entered the thecal sac at the second to third lumbar interspace (L2-3) 
and was threaded up to the tenth thoracic level (T10). Over the course of the last 3 years, the 
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patient presented to our neurosurgery clinic on several instances with intractable torso and lower 
extremity spasticity. The patient’s persistent spasticity resulted in multiple operations for 
intrathecal catheter revision.   Unfortunately, he continued to have residual and increasing 
spasticity that was not relieved by these interventions.   
During an ITB catheter revision in early 2015, he was noted to have a significant amount of 
subarachnoid scar that had prevented the intrathecal catheter from threading to the desired spinal 
level. Post-operatively, he continued to complain of disabling upper trunk spasticity in the area 
extending from his xyphoid to his shoulder. Given his persistent symptoms, we elected to pursue 
an additional operation 3 months later to attempt to mitigate his increased spasticity. Prior to the 
operation there was concern that an intrathecal catheter extending from the lumbar spine would 
not be able to be threaded past the arachnoid adhesions and dural scar in the thoracic spine.  With 
this in mind, we elected to perform bilateral laminectomies at T8 and T7, and a partial 
laminectomy at T6 to facilitate direct placement of an intrathecal catheter in the thoracic spine. 
The intraoperative microscope was utilized to improve visualization in order to ensure that the 
catheter was not infiltrating the spinal cord parenchyma.  The intraoperative microscope allowed 
for direct visualization of the old intrathecal catheter and arachnoid scar that had extended from 
the T8 level to T9-10 levels. We initially attempted to enter the thecal sac at the T8 spinal level 
and thread the intrathecal catheter rostral to the T6 level.  Due to the extensive scar, the 
intrathecal catheter could not be threaded higher than the T6 level. Instead, we elected to place 
the catheter at T6 using fluoroscopic x-ray guidance and then ligated the old, nonfunctional 
lumbar catheter through a separate incision.  
While the patient had some relief of spasms in the upper trunk area postoperatively, the lower 
extremity spasticity and abdominal area spasticity worsened. The lower truncal spasticity was so 
bad that patient frequently complained of worsening diarrhea-type symptoms with incomplete 
evacuation despite adequate bowel regimen.  The patient had been placed on bolus dosing of 
ITB, 40mg oral baclofen daily, and large, scheduled doses of oral valium. His oral valium needs 
were high enough that his family noticed significant cognitive decline.  Unfortunately, his lower 
extremity symptoms persisted.  His spasticity continued to be readily apparent on physical exam 
with lower extremity scissoring.  A CT myelogram showed the patient had a myelographic block 
impeding cerebrospinal fluid flow (CSF) flow as illustrated in Figure 1.  Subsequently, the 
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myelographic block had prevented the ITB from providing adequate coverage in the lower 
extremities.  
Given the patient’s persistent spasticity, two surgical options were discussed with him over 
several clinic visits.  First, the patient could undergo placement of a second baclofen pump with 
catheterization of the caudal intrathecal space.  Second, the patient could undergo a subarachnoid 
to subarachnoid shunting procedure whereby a subarachnoid-to-subarachnoid shunt would be 
placed between the thoracic and lumbar spinal levels.  After extensive discussions, the patient 
elected for the subarachnoid to subarachnoid shunting procedure. 
The patient was taken back to the OR in late 2016 for placement of the subarachnoid to 
subarachnoid shunt as described in Figure 1.  The procedure began with a T4-5 laminectomy and 
an L2-3 laminectomy with intradural lysis of adhesions at both levels.  Next, an intrathecal 
catheter was tunneled into the thecal sac at the L2-3 level.  The baclofen catheter was then 
threaded rostrally from the lumbar laminectomy site up to the T11 vertebral level. Next, a 
standard bactiseal antibiotic catheter was placed intradurally at both the L2-3 and at the T4-5 
laminectomy site, creating a subarachnoid-to-subarachnoid shunt.  The shunt catheter was then 
split with scissors and an inline low-pressure standard shunt valve was connected between the 
two catheters.  The shunt was arranged such that there was an inferior to superior direction of 
flow (e.g., lumbar to thoracic flow pattern). We elected to directly supply the lower thoracic 
spine with ITB and shunt to the upper thoracic spine because the patient’s lower trunk and leg 
symptoms were more difficult to deal with than his upper trunk area. This allowed a baclofen 
gradient with a higher concentration of baclofen in the lower thoracic levels. If the patient’s 
symptoms had been reversed e.g., worse spasticity in the upper extremities and thoracic regions, 
we would have placed the intrathecal catheter in the superior thoracic distribution and reversed 
the direction of CSF flow on the shunt valve from superior to inferior. 
After the operation, the pump flow setting was decreased from 1700 mcg to 700 mcg per day. 
Postoperatively, the patient’s spasticity was significantly improved the day after surgery and 
continued to improve during his hospitalization.  He was monitored in the intensive care unit 
(ICU) for two days and his requirements for oral baclofen decreased substantially while his vital 
signs normalized.  At his first post-operative clinic visit, his pump was further turned down to 
496.6 mcg with continued control of his lower extremity and truncal symptoms.  He was rapidly 
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weaned off his oral valium and now takes minimum oral baclofen as needed for spasticity.  The 
patient is quite satisfied with his post-operative results. 
Discussion 
Post-SCI spasticity is usually unresponsive to oral baclofen owing in part to an impermeable 
blood-brain barrier resulting in low tissue concentration of drug in the spinal cord.2,7 Oral 
baclofen is not well tolerated at high doses due to intolerable adverse effects (e.g., respiratory 
depression) depressed mental status, that limit the ability to provide the dose necessary to 
achieve maximal therapeutic efficacy.2,7 Due to low therapeutic index of oral anti-spasticity 
medications, surgery tends to be the more effective treatment modality. The surgical options 
described in the literature can be grouped into either neuroablative or non-neuroablative 
surgery.5  
ITB infusion is a well-established non-neuroablative surgical treatment for spasticity.2,5 The 
procedure involves intrathecal catheterization and programmable pump implantation with a 
refillable reservoir containing baclofen.6 The pump allows for regulated and targeted delivery of 
baclofen from the reservoir to the desired spinal cord area through the intrathecal catheter.6 
While maximizing its effectiveness, ITB requires lower dosing and prevents systemic 
distribution thus minimizing side effects often seen in oral baclofen. 
In clinical practice, it is not uncommon to have intradural adhesions and scar formation.  These 
pathologies make catheter placement difficult and alter CSF flow dynamics especially after a 
long-term and recurrent intrathecal catheterization. Several case reports in the medical literature 
have reported granulomatous scar formation at the catheter tip preventing effective intrathecal 
delivery of drug.8-11 This case is unique in the sense that the patient sustained a single-level SCI, 
yet developed scar tissue and intradural adhesion that extended through multiple vertebral levels 
presumably creating an anatomical myelographic block as evidenced by the CT myelogram. 
While myelographic block has been associated with several spinal pathologies including 
arachnoiditis, neoplasm, or degenerative diseases, its occurrence after SCI is not well 
documented in the literature.12,13 To our knowledge, this is the first report to hint at the 
occurrence of myelographic block post-SCI. It is possible that the scar tissue and intradural 
adhesions are the result of post-SCI secondary injury, recurrent spinal manipulation or 
intrathecal catheterization from prior spinal surgeries. Regardless of the source of the scar tissue, 
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the fact remains that patient’s increased spasticity over the last three years coincided with the 
growth of extensive scar tissue and intradural adhesions. The myelographic block anatomically 
impedes the flow of baclofen due to poor CSF flow dynamics, thus; greatly increasing the dosage 
required to achieve local therapeutic effect. 
Conclusion  
Post-operatively, the patient was far more satisfied with the outcome of the surgery involving 
multilevel thoracic and lumbar laminectomies with the placement of a subarachnoid-
subarachnoid shunt as a conduit for rostral flow of baclofen. Catheter placement for maximum 
efficacy is not well studied and this case exemplifies catheter insertion failure in a patient with 
multilevel scar tissue where threading of catheter tip is impeded. Placement of two catheters, one 
rostral and the other caudal to the scar location, has not been well documented in the medical 
literature. This patient’s truncal and lower-extremity spasticity posed tremendous challenge 
because he needed rostral and caudal spinal cord coverage to ameliorate his symptoms. 
Unfortunately, the Ascenda catheter is not manufactured with a “Y” or “T” connector, which 
would enable multiple catheters with a single pump source.  
Another option we considered was using two baclofen pumps, but this is not a feasible option 
currently in modern-day medical care. In theory, two baclofen pumps anatomically may provide 
some benefits, but will likely increase susceptibility to baclofen toxicity without necessarily 
achieving adequate dosing for spastic and pain control. This was the reason for leaving the 
ascenda catheters at T11 and placing the shunt catheter up to T4-T5 while inserting an inline 
low-pressure standard shunt valve with the direction of flow from lumbar to thoracic levels.  
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Legends 
Figure 1: Schematic illustration of subarachnoid-subarachnoid shunt placement showing the 
myelographic block at T6, laminectomies at T4-5 and L2-3, ITB catheter, and superior and 
inferior bacteseal antibiotic catheters connected to an inline low-pressure standard shunt 
valve. 
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HIGHLIGHTS 
 
• Spinal cord injury affects about 54 of every million persons in the U.S. 
• The most disabling condition seen in patients with spinal cord injury is spasticity. 
• Intrathecal baclofen is standard for spasticity unresolved with oral baclofen. 
• Scar tissue often develops preventing diffusion of baclofen in desired spinal area. 
• We offer a novel strategy to deal with multilevel scar tissue. 
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ITB = Intrathecal baclofen  
 
SCI= spinal cord injury 
 
CSF= cerebrospinal fluid flow 
